In the field of process of compound powder formulation there is disclosed a novel combination of antituberculosis agents such as Rifampicin (3-[(4-Methyl-1-piperazinyl) iminomethyl] rifamycin SV; in a range of 300 mg to 600 mg preferably in a quantity of 450 mg), Isonicotinic acid hydrazide (4-Pyridinecarboxylic acid hydrazide; in a range of 200 mg to 600 mg preferably in a quantity of 300 mg), Pyrizinamide (Pyrazine-2-carboxamide; in a range of 1000 mg to 1500 mg preferably in a quantity of 1200 mg), Ethambutal (d-N, N'-bis (1-Hydroxymethylpropyl) ethylene diamine in a range of 400 to 800 mg preferably in a quantity of 600 mg,) and antioxidants such as Chromanol ring derivatives such as tocopherol acetate 200 IU to 3000IU, Ascorbic acid in a range of 100 mg to 1000 mg preferably in a quantity of 500 mg producing synergistic beneficial effects in the management of tuberculosis. The formulation on one hand decreases oxidative stress induced lung alveolar damage and on the other hand produces early and enhanced sputum smear negativity up to fifty percent within 15 days as compared to fifteen percent produced by routinely used first four agent combination without antioxidants. This compound powder preparation is synergistic; having better compliance and addition of antioxidants itself is a novel one.
展开▼
